<DOC>
	<DOCNO>NCT01523392</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic effect ticagrelor African American patient stable coronary artery disease .</brief_summary>
	<brief_title>A Pharmacodynamic Study With Ticagrelor African American Patients</brief_title>
	<detailed_description>A Randomized , Open-Label , Multiple Dose , Crossover , Multiple Center Study Antiplatelet Effects Ticagrelor versus Clopidogrel African American Patients Stable Coronary Artery Disease</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision sign date informed consent initiation studyrelated procedure Male female patient age 18 year older Documented stable CAD fulfil take 75100mg ASA daily treatment Females must post menopausal surgically sterile Selfidentified African American Any indication oral anticoagulant ( e.g. , atrial fibrillation , mitral stenosis prosthetic heart valve ) dual antiplatelet treatment ( e.g. , clopidogrel , prasugrel , ASA dose 75 100 mg daily ) study period Patients ACS stent place within 12 month screen Patients history moderate severe hepatic impairment Current smoker , include use tobacco containing product past 1 month randomization Patients require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Stable Coronary Artery Disease , CAD</keyword>
</DOC>